Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) The obesity drug space is becoming increasingly complex and hard to predict.

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) opened trading at 5.34, 0.10 below its previous close of 5.44. Since the slow start THLD has rallied and is currently up 1.65% on volume of 158.36K - average volume is 597.61K.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) a biopharmaceutical company that engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system ...

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) The Food and Drug Administration approved the weight-loss therapy Belviq from Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in June 2012. It took nearly one year for the company to gain marketing approval, ...

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) It wasn't that long ago that obesity drugs were considered a lifestyle drug.

Is Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) an exceptional investment now? Prominent investors are taking a bullish view.

Bullish bets were unusually popular on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) yesterday, with call volume on the drug stock rising to more than three times the expected level.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) A sharp drop in Arena Pharmaceuticals (NASDAQ:ARNA) followed after the company reported quarterly earnings and a withdrawal of its Marketing Authorization Application (�MAA�) in the EU.

Editor's Note: Related tickers: Exxon Mobil Corporation (NYSE:XOM), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), 3M Co (NYSE:MMM), Akamai Technologies, Inc. (NASDAQ:AKAM), QUALCOMM, Inc. (NASDAQ:QCOM), VIVUS, Inc. (NASDAQ:VVUS), ...

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) traded down 9.16% on last day of the week, and closed at $7.63. The stock traded in the band of $7.50 and $7.81 and the range for the 52-week is $2.52 and $13.50.